Role of Finerenone in African American Veterans With Diabetic Kidney Disease (NCT07155694) | Clinical Trial Compass
Not Yet RecruitingPhase 4
Role of Finerenone in African American Veterans With Diabetic Kidney Disease
United States30 participantsStarted 2025-09
Plain-language summary
Primary Objectives: To study podocyte specific injury markers (podocyte specific proteins, PSP) nephrin, podocalyxin and Wilms'Tumor (WT-1) protein in exosomes urine from African American Veterans with albuminuric stage 2 and 3 chronic diabetic kidney disease (DKD), using Empagliflozin or Finerenone or combination therapy.
Secondary Objectives: (1). Correlate changes in exosome-based PSP with standardized biomarkers of kidney injury including urine albumin/creatinine ratio (ACR) and estimated GFR. (2) with systemic inflammatory markers (focusing on vascular and endothelial function) that are already established such as interleukins (IL1, IL6, IL-12), hs-CRP and (3) arterial stiffness measures and with (4) APOL1 mRNA expression levels in peripheral blood derived mononuclear cells (MNC).
Who can participate
Age range20 Years – 90 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Diagnosis of type 2 diabetes (HbA1C at or above 6.5%, or fasting blood glucose of more than 125 or random/ post prandial blood glucose of more than 199mg%)
✓. African American veterans
✓. Age 20-90 years
✓. eGFR ≥25-89 mL/min/1.73 m2 by the CKD-EPI equation)
✓. Albuminuria of 30 mg/g or higher
✓. BMI=18-39.9
✓. Blood pressure controlled to ≤140/90
✓. Ability to provide informed consent before any trial related activities are conducted.
Exclusion criteria
✕. If a patient is on statin, need to be on a stable dose for a month.
✕. Biopsy proven diagnosis of glomerular disease/glomerulonephritis
✕
What they're measuring
1
Urine Exosome Assay
Timeframe: 16 weeks
Trial details
NCT IDNCT07155694
SponsorWashington D.C. Veterans Affairs Medical Center